FDA Granted Priority Review to Breast Cancer Symptom Drug
The agency is reviewing a nonhormonal treatment for vasomotor symptoms caused by breast cancer endocrine therapy.
Updated on Oct. 8, 2026 in Cancer
Live Poll
Should nonhormonal options be prioritized to treat side effects from breast cancer therapies?
The FDA has accepted a supplemental New Drug Application for elinzanetant to treat moderate to severe vasomotor symptoms in patients undergoing endocrine therapy for breast cancer. If approved, this drug would serve as the first nonhormonal treatment option for these specific therapy-related side effects.
Why it matters
Endocrine therapy for hormone receptor-positive breast cancer frequently induces vasomotor symptoms, which can significantly impact patient quality of life. This potential new treatment represents a shift in care by offering an alternative for those who cannot or choose not to use hormonal interventions.
In the Phase 3 OASIS-4 study of 474 women aged 18 to 70, patients receiving 120mg of elinzanetant daily showed a greater reduction in vasomotor symptoms compared to those receiving a placebo. These findings reached statistical significance at both 4 and 12 weeks of treatment.
The players
Bayer
A global life sciences company developing pharmaceuticals, including elinzanetant for menopause and breast cancer-related symptoms.
U.S. Food and Drug Administration
The federal agency responsible for evaluating the safety and efficacy of new drug applications and therapies in the United States.
The details
Elinzanetant works by targeting the neurokinin-1 and -3 receptors in the brain to modulate vasomotor symptoms. By blocking these pathways, the medication aims to reduce the frequency and severity of hot flashes and related discomforts. Reported adverse events for patients taking the medication in clinical trials include somnolence, fatigue, and diarrhea.
Timeline
September 28, 2026: Bayer released news of the FDA priority review acceptance.
October 8, 2026: Article publication date.
Health Landscape
This development marks a potential expansion of elinzanetant, which is already under development for symptoms due to menopause. It aligns with broader clinical efforts to address the side effects of endocrine therapy without relying on hormone-based interventions.
Patients currently experiencing vasomotor symptoms from breast cancer therapy should discuss potential nonhormonal options with their oncology care team. While this review signals progress, the drug is not yet available, and patients should continue following their current prescribed care plan.
The takeaway
The FDA's prioritization of this application highlights a growing focus on improving quality of life for breast cancer survivors. Patients should keep a log of symptom frequency and severity to share with their physicians during upcoming oncology consultations.
Further reading
For additional context on managing long-term treatment side effects, visit our section on Cancer.
More information
Review the Bayer FDA priority review news release for detailed study data.
Source note: This article includes information reported by Oncology Nurse Advisor.
Live Poll
Should nonhormonal options be prioritized to treat side effects from breast cancer therapies?
